Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 4/20 | 0.42 |
| ▸ | NNMT | P40261 | 14/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16943624 | 0.89 | UBA6 (0.41) | UBA6NNMTPIP4K2APRMT5WDR77 | |
| SCHEMBL13170705 | 0.86 | UBA6 (0.43) | UBA6PRMT5WDR77 | |
| SCHEMBL25049137 | 0.80 | NNMT (0.36) | NNMTPIP4K2APRMT5WDR77 | |
| SCHEMBL1947419 | 0.78 | UBA6 (0.41) | UBA6NNMTPRMT5WDR77 | |
| SCHEMBL936138 | 0.78 | UBA6 (0.41) | UBA6NNMTPRMT5WDR77 | |
| SCHEMBL18589317 | 0.78 | UBA6 (0.41) | UBA6NNMTPRMT5WDR77 | |
| SCHEMBL16769947 | 0.77 | PRMT5 (0.44) | UBA6NNMTPIP4K2APRMT5WDR77 | |
| SCHEMBL23892218 | 0.77 | PRMT5 (0.47) | UBA6NNMTPIP4K2APRMT5WDR77 | |
| SCHEMBL25049134 | 0.76 | PIP4K2A (0.46) | UBA6NNMTPIP4K2APRMT5WDR77 | |
| SCHEMBL16967987 | 0.76 | PIP4K2A (0.49) | PIP4K2APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593121-B2 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | UBA6, UBE2V1, UBA1 | UBA6 1/4885NNMT 1932/4885PIP4K2A 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.